Abstract: An electronic device, including a first substrate, a partition wall structure, a pressurizing component, a second substrate, a shell, and multiple first conductive parts, is provided. The first substrate has a through hole, and a first surface and a second surface that are opposite to each other. The partition wall structure is disposed on the first surface and surrounds to form a first chamber. The pressurizing component is disposed on the partition wall structure and covers the first chamber. The pressurizing component includes at least a mass and a vibration membrane. The shell is disposed on the second substrate and jointly forms a second chamber with the second substrate. The first chamber is formed in the second chamber. The multiple first conductive parts are disposed between the first substrate and the second substrate. There is a gap between any two adjacent first conductive parts.

Abstract: Systems and methods are provided for performing random walk graph computing. One method may comprise generating a subset of walkers on a graph, maintaining the generated subset of walkers in a walker pool in a memory, loading a coarse-grained block of the graph from a non-volatile storage into a block buffer of the memory, generating pre-sampled edges for vertices in the coarse-grained block, storing the pre-sampled edges into a pre-sampled edge buffer allocated for the coarse-grained block and moving one or more walkers of the generated subset of walkers using the pre-sampled edges stored in the pre-sampled edge buffer. The generated subset of walkers may have an initial number determined based on a memory space allocated to the walker pool.

Abstract: Systems and methods are provided for performing temporal graph computing. One method may include ordering out edges in a candidate edge set of a vertex in deceasing time, grouping the out edges into a plurality of trunks with at least one of the plurality of trunks being a multi-edge trunk having two or more edges, generating a plurality of alias tables to record content of the plurality of trunks, performing inverse transform sampling on the plurality of trunks to choose a first trunk of interest, determining that the first trunk of interest is a complete multi-edge trunk with a plurality of edges arranged in a plurality of buckets and each bucket has an average weight of a total weight of the plurality of edges and sampling an edge from the plurality of edges by alias table sampling.

Abstract: A method for fabricating a shield gate MOSFET includes forming an epitaxial layer having a first conductivity type, forming a plurality of trenches in the epitaxial layer, forming a first and a second doped regions in the epitaxial layer at a bottom of each of the trenches, wherein the first doped region has a second conductivity type, and the second doped region has the first conductivity type. An insulating layer and a conductive layer as a shield gate are orderly formed in each of the trenches, and a portion of the conductive layer and the insulating layer are removed to expose a portion of the epitaxial layer in the trenches. An inter-gate oxide layer and a gate oxide layer are formed in the trenches, and a control gate is formed on the inter-gate oxide layer in the plurality of trenches.

Abstract: A mapping method for right-turn conflict warning lines at urban road intersections includes: obtaining the conflict data of urban intersections and the driving trajectory information of large vehicles and obtaining the outermost rear wheel trajectory curve and the innermost rear wheel trajectory curve through the driving trajectory information of large vehicles; using the regression model to construct the dynamic model of the right-turn conflict area of large vehicles and obtain the relationship between the parameters of the outermost rear wheel trajectory curve and the innermost rear wheel trajectory curve and the dynamic and static indexes; inputting the dynamic and static indexes of other road intersections into the dynamic model of the right-turn conflict area of large vehicles to obtain the corresponding outermost rear wheel trajectory curve and the innermost rear wheel trajectory curve, and drawing the urban road warning line.

Abstract: A method suitable for driver takeover training of man-machine shared driving vehicle relates to the field of man-machine shared driving technology. The method includes: establishing database, situation-creation, establish a teaching model, take over training, evaluation and analysis of takeover ability. The method divides the driver's takeover behavior into a small operation action through the driver takeover training of the man-machine shared driving vehicle, defines where the driver's eyes need to observe when the takeover reminder appears, how the hands and feet need to be operated, and the sequence of these operations, solves the problems of the driver's tension and being in a flurry in the current sudden takeover reminder. In addition, through the evaluation and analysis of the takeover capability, the method can solve the problem that the existing technology cannot objectively evaluate the driver's takeover capability level.

Abstract: Provided are a method of individual tree crown segmentation from airborne LiDAR data using a novel Gaussian filter and energy function minimization. First, a dual Gaussian filter was designed with automated adaptive parameter assignment and a screening strategy for false treetops. This preserved the geometric characteristics of sub-canopy trees while eliminating false treetops. Second, anisotropic water expansion controlled by the energy function was applied to accurate crown segmentation. This utilized gradient information from the digital surface model and explored the morphological structures of tree crown boundaries as analogous to the maximal valley height difference from surrounding treetops. We demonstrate the generality of our approach using seven diverse plots in the subtropical Gaofeng Forest, China, coupled with ground verification.

Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

Abstract: The present disclosure provides a semiconductor structure including a substrate, a first gate structure, and a second gate structure. The substrate includes at least one first trench group and at least one second trench group spaced apart from each other. The first trench group includes first trenches spaced apart from each other in a first direction and extending in a second direction other than the first direction. The second trench group includes second trenches spaced apart from each other in the second direction and extending in the first direction. The first gate structure is disposed in each of the first trenches and extends in the second direction. The second gate structure is disposed in each of the second trenches and extends in the first direction.

Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: A method for fabricating a shield gate MOSFET includes forming an epitaxial layer having a first conductivity type, forming a plurality of trenches in the epitaxial layer, forming a first and a second doped regions in the epitaxial layer at a bottom of each of the trenches, wherein the first doped region has a second conductivity type, and the second doped region has the first conductivity type. An insulating layer and a conductive layer as a shield gate are orderly formed in each of the trenches, and a portion of the conductive layer and the insulating layer are removed to expose a portion of the epitaxial layer in the trenches. An inter-gate oxide layer and a gate oxide layer are formed in the trenches, and a control gate is formed on the inter-gate oxide layer in the plurality of trenches.

Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

Abstract: A shield gate MOSFET includes an epitaxial layer having a first conductivity type, a plurality of trenches in the epitaxial layer, a shield gate disposed in the trenches, a control gate on the shield gate in the trenches, an insulating layer between the shield gate and the epitaxial layer, a gate oxide layer between the control gate and the epitaxial layer, an inter-gate oxide layer between the shield gate and the control gate, a first doped region in the epitaxial layer at the bottom of the trenches, and a second doped region between the bottom of the trenches and the first doped region. The first doped region has a second conductivity type, and the second doped region has the first conductivity type, and thus the leakage path may be reduced in the presence of the second doped region so as to improve breakdown voltage.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.